Preclinical Evaluation of a Nanoformulated Antihelminthic, Niclosamide, in Ovarian Cancer

Oncotarget - United States
doi 10.18632/oncotarget.7113
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Ovarian Cancer Animal Models for Preclinical Studies and Development of Ovarian Cancer Drugs

JURNAL ILMU KEFARMASIAN INDONESIA
2019English

Photodynamic Diagnosis of Ovarian Cancer Using Hexaminolaevulinate: A Preclinical Study

British Journal of Cancer
Cancer ResearchOncology
2003English

Activity of PXD101, a Histone Deacetylase Inhibitor, in Preclinical Ovarian Cancer Studies

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Preclinical Evaluation of a GFRA1 Targeted Antibody-Drug Conjugate in Breast Cancer

Oncotarget
Oncology
2018English

Preclinical Evaluation of Exemestane as a Novel Chemotherapy for Gastric Cancer

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Correction: Niclosamide and Its Analogs Are Potent Inhibitors of WNT/Β-Catenin, mTOR and STAT3 Signaling in Ovarian Cancer

Oncotarget
Oncology
2018English

A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer

Science Translational Medicine
Medicine
2012English

Preclinical Immunotherapy With Cytokine-Induced Killer Lymphocytes Against Epithelial Ovarian Cancer

Scientific Reports
Multidisciplinary
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy